TCGA-63-A5ML-01A-31R-A27Q-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.430
- INTERFERON_ALPHA_RESPONSE+0.360
- MITOTIC_SPINDLE+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- MYC_TARGETS_V1+0.240
- PI3K_AKT_MTOR_SIGNALING+0.210
- PROTEIN_SECRETION+0.190
- APICAL_SURFACE+0.180
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.410
- IL6_JAK_STAT3_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.390
- PANCREAS_BETA_CELLS-0.340
- ALLOGRAFT_REJECTION-0.330
- ANGIOGENESIS-0.330
- COAGULATION-0.330
- INFLAMMATORY_RESPONSE-0.330
- TGF_BETA_SIGNALING-0.330
- COMPLEMENT-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.854 |
| 2 | TCGA-77-A5GF-01A-21R-A27Q-07 | — | cohortSQ2 | 0.847 |
| 3 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.798 |
| 4 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.796 |
| 5 | TCGA-43-6143-01A-11R-1820-07 | — | cohortMD1 | 0.790 |
| 6 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.786 |
| 7 | TCGA-O2-A52S-01A-11R-A262-07 | — | cohortSQ2 | 0.771 |
| 8 | TCGA-E2-A109-01A-11R-A10J-07 | — | B | 0.768 |
| 9 | R4 | — | — | 0.767 |
| 10 | TCGA-EW-A1PC-01B-11R-A21T-07 | — | C | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |